Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care ...

The following is a summary of “Biological characterization and clinical significance of cuproptosis-related genes in lung ...

Patients with relapsed or refractory large B-cell lymphoma who received epcoritamab or glofitamab in real-world settings ...

FARMINGDALE, N.Y, Jan. 14, 2025 (GLOBE NEWSWIRE) -- (NYSE: ENZ) (“Enzo” or the “Company”) today announced that it was ...

Many cancers upregulate an amino acid transporter to fuel their growth, making this protein a promising tool in tumor ...

USA News Group News Commentary – As the new year begins, the American Association for Cancer Research (AACR) has highlighted ...

Enzo Biochem, Inc. (NYSE: ENZ) ("Enzo" or the "Company") today announced that it was notified by the New York Stock Exchange (the "NYSE") that it is ...

The firm is using immunohistochemistry to gauge biomarker expression before enrolling patients in a trial of its CLDN 18.2-directed antibody-drug conjugate.

NeoGenomics (NEO – Research Report) received a Hold rating and price target from Benchmark Co. analyst Bruce Jackson today. The company’s ...

The global Spatial Genomics & Transcriptomics market is expected to grow to USD 995.7 Million by 2029, up from USD 554.5 ...

Zentalis Pharmaceuticals has won a U.S. Food and Drug Administration fast-track designation for its lead product candidate azenosertib for certain cancer patients with high levels of the Cyclin E1 ...